Speciality Generic Pharmaceutical Company

Tai Yu leverages innovative technologies, new thinking and breakthrough ideas to bring affordable medicines to patients with competence, care, compassion, commitment.

Quality without Compromise

At Tai-Yu, quality is the center of all activities and we are passionate about adding vision and value through highest standards of safe, effective and affordable medicine

PIC/S GMP Certified

We have leveraged our inherent strengths of world-class quality equipment and operations in all our manufacturing facilities to develop, manufacture and deliver a rich portfolio of medicine in major therapeutic areas.


We are in constant search of partners that match our values, work ethics and commitment to patients. Our track-record of successful collaborations includes in/out licensing of products.


Tai-Yu – The Tai-Yu chemical and pharmaceutical co., Ltd is one of the Taiwan's leading pharmaceutical companies located in Hsinchu, a high tech city in northern Taiwan. The company was found in 1977 with the aim to deliver high-quality generic medications to the patients across globe. With its pioneering and entrepreneurial spirit Tai-Yu, Inc. is committed to achieving its vision and mission of delivering high-quality generic medications trusted by healthcare professionals and patients across geographies. Over a period of three decades Tai-Yu Inc. has built a strong brand reputation and emotional connect with doctors and patients.The company has state-of-the-art research and development unit, quality control and quality assurance department and PIC/S GMP certified manufacturing facility spreading across 5 acres. Tai-Yu enjoys a rich manufacturing experience of 40 years and has robust product portfolio spread over major product areas encompassing CVS, CNS, Antibiotics, Gastroenterologicals, Anti-Diabetics and Anti-Allergic. Tai-Yu is governed under the guiding principles of providing affordable medication to patients with competence, care, compassion, commitment. We at Tai Yu embrace our responsibility to create a positive impact in the recovery of patients. Going forward, Tai-Yu seeks to differentiate itself through patient-centricity, innovation, entrepreneurship, trustworthiness and values-driven business operations.

News & Events

2nd June 2017- AstraZeneca has presented late-stage data showing that patients taking its ovarian cancer therapy Lynparza not only benefitted from improved progression-free survival but also reported similar quality of life to those taking a placebo.

june 2016 – Patients with classical Hodgkin lymphoma (cHL) living in England and Wales could now become the first to get routine access on the NHS to Bristol-Myers Squibb’s immunotherapy Opdivo after a u-turn saw cost regulators provisionally back the drug.

Teva has unveiled data showing that its experimental migraine drug fremanezumab hit key efficacy targets in a late stage trial, on the back of which it expects to submit regulatory filings later this year.

It is now looking likely that Sanofi’s Cerdelga will be funded on the NHS in England and Wales to treat type 1 Gaucher disease, after a u-turn by cost regulators.

The NHS could be faced with having to pay nearly half a billion pounds more if British expats decide to return to the UK because their right to healthcare in EU countries is withdrawn after Brexit.

Complex generics are off-patent versions of drugs that involve complex APIs such as low molecular weight heparin (LMWH), peptides, complex mixtures, or natural source products; controlled substances, complex formulations such as liposomes, iron colloids; complex route of delivery; or a drug-device combination such as dry powder inhaler (DPI), metered dose inhaler (MDI), nasal spray, or transdermal system.

Gilead has unveiled data from a batch of late-stage trials showing that its investigational HIV therapy bictegravir was non-inferior to ViiV Healthcare’s flagship drug dolutegravir in suppressing levels of the virus.

Leading medical organisations in the UK are calling for continued collaboration between researchers in the UK and Europe during and after Brexit as a new reports highlights the value of such partnerships and their benefit to patients.

Featured Products